1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Date not available
Admin
News Article

Transcenta Holding Announces Approval to Initiate Phase II Clinical Trial of TST002 (Blosozumab)

Transcenta Holding announced that it has received approval from the China Centre for Drug Evaluation (CDE) to conduct a Phase II clinical trial of their drug candidate TST002, also known as Blosozumab. Blosozumab is a humanised anti-sclerostin monoclonal antibody intended for the treatment of osteoporosis and other bone loss diseases.

The Phase II clinical trial will focus on evaluating the safety, tolerability, and pharmacokinetics of TST002 after both single and multiple intravenous administrations. The study will involve patients with reduced bone mineral density, aiming to assess the drug's effects on bone health.

TST002, also known as Blosozumab, is a humanised anti-sclerostin monoclonal antibody that holds promise as a drug candidate for treating osteoporosis and other bone loss diseases. Its unique feature lies in its dual effect, possessing both anabolic and anti-resorptive properties. This means that it can stimulate bone formation while also inhibiting bone absorption, resulting in a rapid increase in bone mineral density (BMD) and bone strength.

By blocking the activity of sclerostin, a protein that negatively regulates bone formation, TST002 promotes bone-building processes, making it an effective approach in increasing BMD and reducing the risk of bone fractures.

Currently there is no approved anti-sclerostin antibody therapy in China yet although Romosozumab from Amgen has been approved in the United States, Europe and Japan.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!